Welcome to the e-CCO Library!

P558: Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study.
Year: 2022
Source: ECCO'22
Authors: Cottron, C.(1);Treton, X.(2);Altwegg, R.(3);Reenaers, C.(4);Amiot, A.(5);Fumery, M.(6);Vuitton, L.(7);Peyrin-Biroulet, L.(8);Bouguen, G.(9);Dewit, O.(10);Nancey, S.(11);Caillo, L.(12);Roblin, X.(13);Beylot-Barry, M.(14);Rivière, P.(1);Laharie, D.(1);
Created: Friday, 11 February 2022, 3:56 PM
P558: The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rubin D.T.*1, Panés J.2, Lindsay J.O.3, Vermeire S.4, Yarlas A.5, Bayliss M.5, Cappelleri J.C.6, Maher S.5, Bushmakin A.G.6, Chen L.A.7, Manuchehri A.8, Healey P.6

Created: Wednesday, 20 February 2019, 10:36 AM
P559 Effect of vedolizumab and ustekinumab on articular manifestations in patients with inflammatory bowel disease refractory or intolerant to anti-TNF therapy: An observational prospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

O. Britschu1, A. Meyer2, J.E. Gottenberg2, J.M. Reimund1, B. Caron1

Created: Thursday, 30 January 2020, 10:12 AM
P559: Cannabis Improves Sleep Quality in Patients with Inflammatory Bowel Diseases in a Prospective Observational Study
Year: 2022
Source: ECCO'22
Authors: Hirsch, A.(1);Seidenberg, C.(2);Fliss Isakov, N.(1);Meiri, D.(3);Maharshak, N.(1);
Created: Friday, 11 February 2022, 3:56 PM
P559: Efficacy of Ustekinumab in the treatment of patients with Crohn’s disease with failure to previous conventional or biologic therapy: an observational real-life study
Year: 2021
Source: ECCO'21 Virtual
Authors: Miranda, A.(1);Cuomo, A.(2);Camera, S.(2);Ciacci, C.(3);De Filippo, F.R.(3);Gravina, A.G.(1);D'Onofrio, V.(4);Melina , R.(4);Manguso, F.(5);PRIADKO, K.(1);Facchiano, A.(1);Bennato, R.(6);D'Onofrio, R.(1);Cuomo, R.(7);Mucherino, C.(8);Romano, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P559: Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Iborra*1, N. García-Morales1, S. Rubio2, O. Nantes Castillejo2, F. Bertoletti3, E. García-Planella3, M. Calvo4, I. Vera4, C. Taxonera5, C. Alba5, M. Boscá-Watts6, D. Martí-Aguado6, M. P. Ballester Ferrer6, M. Sierra7, N. Cano-Sanz7, N. Mancenido8, R. Pajares-Villarroya8, B. Beltrán1, A. Cañada9, P. Nos1

Created: Friday, 22 February 2019, 9:41 AM
P559: SARS-CoV-2 vaccination does not increase the risk for flares in Inflammatory Bowel Disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rossier, L.(1)*;Seibold, F.(2);
Created: Friday, 14 July 2023, 11:05 AM
P559: Tacrolimus as a topical therapy for perianal Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Nanaeva1*, M. Shapina2, I. Khalif1

Created: Thursday, 21 February 2019, 9:14 AM
P559: Treatment goals in IBD: a perspective from patients and their partners
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Peek-Kuijt N., Aantjes M., Verwey M., van der Meulen-de Jong A., Maljaars P.

Created: Wednesday, 20 February 2019, 10:36 AM
P560 Incidence of joint symptoms in patients with inflammatory bowel disease on treatment with vedolizumab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.A. RUIZ-RAMIREZ1, P. Rodríguez-Merlos2, C. Suarez1, C. Plasencia-Rodríguez2, V. Navarro-Compán2, J. Poza1, E. Martin-Arranz1, M. Sanchez-Azofra1, J.L. Rueda-Garcia1, L. Garcia-Ramirez3, K. Franco2, G. Bonilla2, D. Peiteado2, A. Balsa2, M.D. Martin-Arranz1

Created: Thursday, 30 January 2020, 10:12 AM
P560: Application of a clinical decision support tool for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicenter study
Year: 2022
Source: ECCO'22
Authors: Kim, K.(1);Hong, S.W.(1);Park, J.H.(1);Hwang, S.W.(1,2);Park, S.H.(1,2);Yang, D.H.(1);Byeon, J.S.(1);Myung, S.J.(1);Yang, S.K.(1,2);Yoo, J.H.(3);Boo, S.J.(4);Kim, E.S.(5);Lee, J.(6);Kim, K.O.(7);Ye, B.D.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P560: Clinical outcomes of vedolizumab maintenance treatment for Korean patients with inflammatory bowel disease who failed anti-TNF therapy: A KASID prospective multicenter cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Oh, K.(1);Kim, J.(2);Kim, N.(3);Yoon, H.(4);Lee, K.M.(5);Park, D.I.(6);Choi, C.H.(7);Lee, C.K.(8);Eun, C.S.(9);Kang, S.B.(10);Kim, E.S.(11);Kim, Y.S.(12);Jung, S.A.(13);Jung, Y.(14);Kim, T.O.(15);Park, S.J.(16);Im, J.P.(17);Seo, G.S.(18);Ye, B.D.(19);
Created: Wednesday, 2 June 2021, 4:12 PM
P560: Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ben-Horin, S.(1);Salomon, N.(1)*;Karampekos, G.(2);Viazis, N.(2);Lahat, A.(1);Ungar, B.(1);Eliakim, R.(1);Kriger-Sharabi, O.(3);Reiss-Mintz, H.(4);Yanai, H.(5);Dotan, I.(6);Zittan, E.(7);Maharshak, N.(8);Hirsch, A.(9);Weitman, M.(10);Mantzaris, G.J.(2);Kopylov, U.(1);
Created: Friday, 14 July 2023, 11:05 AM
P560: Granulocyte–monocyte apheresis combination therapy after loss of response to anti-TNF drugs
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Rodríguez-Lago1*, L. Sempere2, A. Gutiérrez2,3, B. Beltrán4, E. Saez4, E. Hinojosa5, M. Mora5, F. Cañete6, M. Mañosa6, S. Khorrami7, D. Ginard7, J.L. Cabriada1

Created: Thursday, 21 February 2019, 9:14 AM
P560: Multi-centric randomised study comparing interventional vs. non-interventional treatment for anal fistulas in patient with Crohn’s disease and adalimumab treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Abramowitz1, D. Bouchard2, L. Siproudhis3, F. Pigot*2, P. Roumeguere-Blond4, H. Pillant5, B. Vinson-Bonnet6, J-L. Faucheron7, A. Senejoux8, G. Bonnaud9, G. Meurette10, C. Train11, G. Staumont12

Created: Friday, 22 February 2019, 9:41 AM
P560: Trough levels at induction: impact on long term response when re-initiating infliximab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Liefferinckx C.*1, Minsart C.2, Toubeau J.-F.3, Cremer A.4, Amininejad L.4, Quertinmont E.2, Devière J.4, Gils A.5, Van Gossum A.4, Franchimont D.4

Created: Wednesday, 20 February 2019, 10:36 AM
P561 The management of Crohn’s disease (CD) patients post ileocaecal resection: a multicentre, regional audit in Northern England
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. BATCHELOR1, A. Speight2, Gastroenterology Research and Audit for Northern Trainees

Created: Thursday, 30 January 2020, 10:12 AM
P561: A comparison of medication adherence and persistence between intravenous biologics and oral small-molecule therapies
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Kane1, K. Moran2, K. Null2, Z. Huang2, T. Lissoos2*

Created: Thursday, 21 February 2019, 9:14 AM
P561: Can we predict adherence to treatment in IBD patients?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Naftali T.*1, Ein Dor A.2,3, Ruhimovich N.4, Shitrit A.B.5, Sklerovsky Benjaminov F.2,4, Matalon S.2,3, Shirin H.3,6, Konikoff F.M.1,2, Broide E.3,6

Created: Wednesday, 20 February 2019, 10:36 AM
P561: Clinical utility of therapeutic drug monitoring of adalimumab using a point of care test
Year: 2022
Source: ECCO'22
Authors: Stevens, T.(1);Teichert, C.(1);Volkers, A.(1);Mostafavi Montazeri, N.(1);Bahur, B.(2);Bray, K.(3);D'Haens, G.(1);
Created: Friday, 11 February 2022, 3:56 PM